The UK medtech industry is urging health care decision makers to take a more concerted approach to controlling cardiovascular disease (CVD), a condition that has direct health care costs of £7.4bn ($10.1bn) annually in England alone.
Costs to the wider economy are more than double that figure, at £15.8bn, according to a new Health Check report from the Association of British HealthTech Industries (ABHI). The report...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?